Dry eye disease (DED) develops when the eyes produce too few tears, or the tears evaporate too quickly. As a result, the illness may affect one or both eyes. A chronic corneal surface condition is marked by persistent burning symptoms or irritation that can further lead to inflammatory damage to the conjunctiva and cornea if they are not treated in the early stage. Common risk factors related to DED include low humidity environments, autoimmune disorders, advancing age, and systemic medications.
The cases of dry eye disease are increasing rapidly, with a higher global prevalence that ranges from 20% to 50% in different regions. Women are more prone to get dry eye disease than men, with increased prevalence after menopause. Estrogen alone or progestin can worsen symptoms, and androgen treatment improves dry eye symptoms.
Report Key Takeaways
Recommended Drugs & Treatment for Dry Eye Disease:
Most persons with infrequent or mild dry eye symptoms can get by using over-the-counter eye drops daily (artificial tears). You have additional options if your symptoms are severe and persistent. What you do will be determined by the cause of your dry eyes.
Drugs
Oil glands can’t secrete oil into your tears if they’re inflamed around the edge of your eyelids. Antibiotics for eye disease are often taken by mouth, although some are prescribed with ointments or eye drops.
Eye Drops
Prescription eye drops containing the immune-suppressing medicine cyclosporine or corticosteroids can help manage inflammation on the surface of your eyes. However, because of the potential for adverse effects, corticosteroids are not recommended for long-term use.
Contact Lenses
Inquire with your doctor about modern contact lenses that are developed to help those who suffer from dry eyes. Contact lenses with unique features that protect the eyes’ surface are also preferred for certain patients with significant issues with dry eyes. Scleral lenses, often known as bandage lenses, are contact lenses.
Recent Developments Related to Dry Eye Disease
- Aerie Pharmaceuticals has recently conducted a Phase III clinical trial for developing the AR-15512 ophthalmic solution. The solution under development is a target for treating dry eye disease. During this phase III trial, the company also dosed the first participant. The newly developed solution will be evaluated for the treatment of signs and symptoms in the COMET-2 study.
- The FDA has approved varenicline nasal spray 0.03 mg. The spray is developed for specifically treating signs of dry eye disease. The FDA approved varenicline nasal spray based on the results of different levels of clinical trials such as MYSTIC, ONSET-1, and ONSET-2. In these trials, more than 1000 individuals participated who had mild to severe DED.
Major Players Working on Dry Eye Disease
Some of the key companies that are involved with the research and development activities related to dry eye disease include Novartis AG. Akorn, Inc., Santen Pharmaceutical Co. Ltd., Johnson & Johnson, Inc., Medicom Healthcare Ltd., Allergan Plc., and Similasan Corporation.
Key Reasons to Purchase This Report
- The pipeline insight encompasses an in-depth assessment of existing drugs available in the industry and carry out the competitive study with the newly developed drugs for the target disease.
- It is a helpful guide for the stakeholders across the industry, including distributors, product manufacturers, practitioners, patients, and other industry experts.
- It sheds light on the leading companies operating in this arena, covering their recent activities in terms of product developments, expansions, and strategic collaborations.
